Welcome to Bard Peripheral Vascular – where a tradition of vascular innovation spans decades of focusing on improving the quality of patients’ lives.
From C. R. Bard’s first arterial prosthesis developed in 1954, Bard and the division of Bard Peripheral Vascular have demonstrated commitment to innovative medical technology by introducing surgical and interventional devices for peripheral vascular patency, while providing exceptional service and support to surgeons, interventionalists and radiologists.
The first commercially available ePTFE graft (expanded polytetraflouroethylene) was used for AV access, introduced by IMPRA, Inc. in 1975. ePTFE is used in vascular prosthetic applications like grafts, which are commonly used to surgically bypass diseased arteries or to provide blood access for hemodialysis. ePTFE can also be used to cover stents, is readily accepted by body tissue, pliable, is easily sutured. It has an excellent history as an implant material in many applications.
BARD markets its products and services worldwide to hospitals, individual health care professionals, extended care facilities, and alternate site facilities.
BARD pioneered the development of single-patient-use medical products for hospital procedures; today BARD is dedicated to pursuing technological innovations that offer superior clinical benefits while helping to reduce overall costs.